{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:14:07Z","timestamp":1761675247434},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T00:00:00Z","timestamp":1126569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T00:00:00Z","timestamp":1126569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Ductal carcinoma <jats:italic>in situ<\/jats:italic> (DCIS) is a noninvasive premalignant lesion and is considered a precursor to invasive carcinoma. DCIS accounts for nearly 20% of newly diagnosed breast cancer, but the lack of experimentally amenable <jats:italic>in vivo<\/jats:italic> DCIS models hinders the development of treatment strategies. Here, we demonstrate the utility of a mouse transplantation model of DCIS for chemoprevention studies using selective estrogen receptor modulators (SERMs). This model consists of a set of serially transplanted lines of genetically engineered mouse mammary intraepithelial neoplasia (MIN) outgrowth (MIN-O) tissue that have stable characteristics. We studied the ovarian-hormone-responsiveness of one of the lines with a particular focus on the effects of two related SERMs, tamoxifen and ospemifene.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>The estrogen receptor (ER) status and ovarian-hormone-dependence of the mouse MIN outgrowth tissue were determined by immunohistochemistry and ovarian ablation. The effects of tamoxifen and ospemifene on the growth and tumorigenesis of MIN outgrowth were assessed at 3 and 10 weeks after transplantation. The effects on ER status, cell proliferation, and apoptosis were studied with immunohistochemistry.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>The MIN-O was ER-positive and ovarian ablation resulted in reduced MIN-O growth and tumor development. Likewise, tamoxifen and ospemifene treatments decreased the MIN growth and tumor incidence in comparison with the control (<jats:italic>P<\/jats:italic> &lt; 0.01). Both SERMs significantly decreased cell proliferation. Between the two SERM treatment groups, there were no statistically significant differences in MIN-O size, tumor latency, or proliferation rate. In contrast, the ospemifene treatment significantly increased ER levels while tamoxifen significantly decreased them.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>Tamoxifen and ospemifene inhibit the growth of premalignant mammary lesions and the progression to invasive carcinoma in a transplantable mouse model of DCIS. The inhibitory effects of these two SERMs are similar except for their effects on ER modulation. These differences in ER modulation may suggest different mechanisms of action between the two related SERMs and may portend different long-term outcomes. These data demonstrate the value of this model system for preclinical testing of antiestrogen or other therapies designed to prevent or delay the malignant transformation of premalignant mammary lesions in chemoprevention.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/bcr1317","type":"journal-article","created":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T18:13:51Z","timestamp":1126635231000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ"],"prefix":"10.1186","volume":"7","author":[{"given":"Ruria","family":"Namba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence JT","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannie E","family":"Maglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik T","family":"McGoldrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephenie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory T","family":"Wurz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W","family":"DeGregorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander D","family":"Borowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol L","family":"MacLeod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D","family":"Cardiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey P","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,9,13]]},"reference":[{"key":"1296_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.suronc.2003.09.001","volume":"12","author":"J Cuzick","year":"2003","unstructured":"Cuzick J: Treatment of DCIS \u2013 results from clinical trials. Surg Oncol. 2003, 12: 213-219. 10.1016\/j.suronc.2003.09.001.","journal-title":"Surg Oncol"},{"key":"1296_CR2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1158\/1535-7163.941.3.8","volume":"3","author":"JE Maglione","year":"2004","unstructured":"Maglione JE, McGoldrick ET, Young LJT, Namba R, Gregg JP, Liu L, Moghanaki D, Ellies LG, Borowsky AD, Cardiff RD, et al: Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes. Mol Cancer Ther. 2004, 3: 941-953.","journal-title":"Mol Cancer Ther"},{"key":"1296_CR3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1158\/1541-7786.453.2.8","volume":"2","author":"R Namba","year":"2004","unstructured":"Namba R, Maglione JE, Young LJ, Borowsky AD, Cardiff RD, MacLeod CL, Gregg JP: Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ. Mol Cancer Res. 2004, 2: 453-463.","journal-title":"Mol Cancer Res"},{"key":"1296_CR4","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/sj.onc.1203277","volume":"19","author":"RD Cardiff","year":"2000","unstructured":"Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, et al: The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene. 2000, 19: 968-988. 10.1038\/sj.onc.1203277.","journal-title":"Oncogene"},{"key":"1296_CR5","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0002-9440(10)63568-7","volume":"163","author":"EY Lin","year":"2003","unstructured":"Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW: Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003, 163: 2113-2126.","journal-title":"Am J Pathol"},{"key":"1296_CR6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/nrc946","volume":"2","author":"SM Dilworth","year":"2002","unstructured":"Dilworth SM: Polyoma virus middle T antigen and its role in identifying cancer-related molecules. Nat Rev Cancer. 2002, 2: 951-956. 10.1038\/nrc946.","journal-title":"Nat Rev Cancer"},{"key":"1296_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987, 235: 177-182.","journal-title":"Science"},{"key":"1296_CR8","doi-asserted-by":"publisher","first-page":"6967","DOI":"10.1073\/pnas.102172399","volume":"99","author":"KV Desai","year":"2002","unstructured":"Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R, Furth P, Hunter K, Kucherlapati R, et al: Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA. 2002, 99: 6967-6972. 10.1073\/pnas.102172399.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1296_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0002-9440(10)64269-1","volume":"161","author":"A Rosner","year":"2002","unstructured":"Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR, MacLeod CL, Shyamala G, Gillgrass AE, Cardiff RD: Pathway pathology: histological differences between ErbB\/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol. 2002, 161: 1087-1097.","journal-title":"Am J Pathol"},{"key":"1296_CR10","first-page":"8298","volume":"61","author":"JE Maglione","year":"2001","unstructured":"Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, Nicholson B, Cardiff RD, MacLeod CL: Transgenic polyoma middle-T mice model premalignant mammary disease. Cancer Res. 2001, 61: 8298-8305.","journal-title":"Cancer Res"},{"key":"1296_CR11","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1158\/1055-9965.1558.13.10","volume":"13","author":"MD Althuis","year":"2004","unstructured":"Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME: Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004, 13: 1558-1568.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1296_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1022133219353","volume":"78","author":"C Dabrosin","year":"2003","unstructured":"Dabrosin C, Palmer K, Muller WJ, Gauldie J: Estradiol promotes growth and angiogenesis in polyoma middle T transgenic mouse mammary tumor explants. Breast Cancer Res Treat. 2003, 78: 1-6. 10.1023\/A:1022133219353.","journal-title":"Breast Cancer Res Treat"},{"key":"1296_CR13","doi-asserted-by":"crossref","unstructured":"Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998, 351: 1451-1467. 10.1016\/S0140-6736(97)11423-4.","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"1296_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s002040100244","volume":"75","author":"P Carthew","year":"2001","unstructured":"Carthew P, Lee PN, Edwards RE, Heydon RT, Nolan BM, Martin EA: Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat. Arch Toxicol. 2001, 75: 375-380. 10.1007\/s002040100244.","journal-title":"Arch Toxicol"},{"key":"1296_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(05)74803-0","volume":"365","author":"A Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005, 365: 60-62. 10.1016\/S0140-6736(05)74803-0.","journal-title":"Lancet"},{"key":"1296_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3816\/CBC.2005.n.006","volume":"6","author":"M Kalidas","year":"2005","unstructured":"Kalidas M, Brown P: Aromatase inhibitors for the treatment and prevention of breast cancer. Clin Breast Cancer. 2005, 6: 27-37.","journal-title":"Clin Breast Cancer"},{"key":"1296_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1040-8428(02)00022-7","volume":"43","author":"KC Morello","year":"2002","unstructured":"Morello KC, Wurz GT, DeGregorio MW: SERMs: current status and future trends. Crit Rev Oncol Hematol. 2002, 43: 63-76.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1296_CR18","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","volume":"17","author":"JM Harvey","year":"1999","unstructured":"Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999, 17: 1474-1481.","journal-title":"J Clin Oncol"},{"key":"1296_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0378-4347(98)00571-4","volume":"724","author":"TL Taras","year":"1999","unstructured":"Taras TL, Wurz GT, Hellmann-Blumberg U, DeGregorio MW: Quantitative analysis of Z-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol in human plasma using high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1999, 724: 163-171. 10.1016\/S0378-4347(98)00571-4.","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"1296_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0960-0760(01)00066-8","volume":"77","author":"TL Taras","year":"2001","unstructured":"Taras TL, Wurz GT, DeGregorio MW: In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol. 2001, 77: 271-279. 10.1016\/S0960-0760(01)00066-8.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1296_CR21","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1038\/sj.onc.1208597","volume":"24","author":"X Zhang","year":"2005","unstructured":"Zhang X, Podsypanina K, Huang S, Mohsin SK, Chamness GC, Hatsell S, Cowin P, Schiff R, Li Y: Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations. Oncogene. 2005, 24: 4220-4231. 10.1038\/sj.onc.1208597.","journal-title":"Oncogene"},{"key":"1296_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1023\/A:1005833811584","volume":"44","author":"M Crump","year":"1997","unstructured":"Crump M, Sawka CA, DeBoer G, Buchanan RB, Ingle JN, Forbes J, Meakin JW, Shelley W, Pritchard KI: An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat. 1997, 44: 201-210. 10.1023\/A:1005833811584.","journal-title":"Breast Cancer Res Treat"},{"key":"1296_CR23","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1200\/JCO.1986.4.9.1326","volume":"4","author":"RB Buchanan","year":"1986","unstructured":"Buchanan RB, Blamey RW, Durrant KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol. 1986, 4: 1326-1330.","journal-title":"J Clin Oncol"},{"key":"1296_CR24","doi-asserted-by":"crossref","first-page":"951s","DOI":"10.1158\/1078-0432.951s.11.2","volume":"11","author":"M Dowsett","year":"2005","unstructured":"Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, et al: Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005, 11: 951s-958s.","journal-title":"Clin Cancer Res"},{"key":"1296_CR25","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1200\/JCO.2005.01.172","volume":"23","author":"MC Gutierrez","year":"2005","unstructured":"Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M: Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005, 23: 2469-2476. 10.1200\/JCO.2005.01.172.","journal-title":"J Clin Oncol"},{"key":"1296_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","volume":"10","author":"EM Rutanen","year":"2003","unstructured":"Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O: Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause. 2003, 10: 433-439. 10.1097\/01.GME.0000063609.62485.27.","journal-title":"Menopause"},{"key":"1296_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0378-5122(02)00206-2","volume":"43","author":"SK Voipio","year":"2002","unstructured":"Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU: Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas. 2002, 43: 207-214. 10.1016\/S0378-5122(02)00206-2.","journal-title":"Maturitas"},{"key":"1296_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1210\/endo.141.2.7342","volume":"141","author":"Q Qu","year":"2000","unstructured":"Qu Q, Zheng H, Dahllund J, Laine A, Cockcroft N, Peng Z, Koskinen M, Hemminki K, Kangas L, Vaananen K, et al: Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology. 2000, 141: 809-820. 10.1210\/en.141.2.809.","journal-title":"Endocrinology"},{"key":"1296_CR29","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/jnci\/57.2.331","volume":"57","author":"D Medina","year":"1976","unstructured":"Medina D, Warner MR: Mammary tumorigenesis in chemical carcinogen-treated mice. IV. Induction of mammary ductal hyperplasias. J Natl Cancer Inst. 1976, 57: 331-337.","journal-title":"J Natl Cancer Inst"},{"key":"1296_CR30","first-page":"2425","volume":"63","author":"X Yang","year":"2003","unstructured":"Yang X, Edgerton SM, Kosanke SD, Mason TL, Alvarez KM, Liu N, Chatterton RT, Liu B, Wang Q, Kim A, et al: Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. Cancer Res. 2003, 63: 2425-2433.","journal-title":"Cancer Res"},{"key":"1296_CR31","first-page":"2798","volume":"62","author":"SC Hewitt","year":"2002","unstructured":"Hewitt SC, Bocchinfuso WP, Zhai J, Harrell C, Koonce L, Clark J, Myers P, Korach KS: Lack of ductal development in the absence of functional estrogen receptor alpha delays mammary tumor formation induced by transgenic expression of ErbB2\/neu. Cancer Res. 2002, 62: 2798-2805.","journal-title":"Cancer Res"},{"key":"1296_CR32","first-page":"273","volume":"60","author":"S Menard","year":"2000","unstructured":"Menard S, Aiello P, Tagliabue E, Rumio C, Lollini PL, Colnaghi MI, Balsari A: Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model. Cancer Res. 2000, 60: 273-275.","journal-title":"Cancer Res"},{"key":"1296_CR33","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/ijc.11092","volume":"105","author":"P Nanni","year":"2003","unstructured":"Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Iezzi M, Ricci C, Astolfi A, Croci S, Marangoni F, et al: Prevention of HER-2\/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Int J Cancer. 2003, 105: 384-389. 10.1002\/ijc.11092.","journal-title":"Int J Cancer"},{"key":"1296_CR34","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1158\/0008.5472.CAN-04-3869","volume":"65","author":"D Medina","year":"2005","unstructured":"Medina D, Kittrell FS, Hill J, Shepard A, Thordarson G, Brown P: Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis. Cancer Res. 2005, 65: 3493-3496.","journal-title":"Cancer Res"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr1317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/bcr1317\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/bcr1317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T11:02:20Z","timestamp":1728385340000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/bcr1317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,13]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,12]]}},"alternative-id":["1296"],"URL":"https:\/\/doi.org\/10.1186\/bcr1317","relation":{},"ISSN":["1465-542X"],"issn-type":[{"type":"electronic","value":"1465-542X"}],"subject":[],"published":{"date-parts":[[2005,9,13]]},"assertion":[{"value":"23 May 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2005","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2005","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2005","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R881"}}